




TORRENT PHARMACEUTICALS LIMITED

Registered Office: Torrent House, Off Ashram Road, Ahmedabad - 380 009, Ph.: +91 79 26599000 Fax: + 91 79 26582100
CIN: L24230GJ1972PLC002126; Website:www.torrentpharma.com; Email: investorservices@torrentpharma.com

(Rs. in crores except per share data)

Statement of Standalone Audited Financial Results for the Quarter and Nine Months Ended 31-Dec-2019


Particulars	Quarter ended			Nine Months ended		Year ended
	31-Dec-2019	30-Sep-2019	31-Dec-2018	31-Dec-2019	31-Dec-2018	31-Mar-2019
Revenue						
Net sales	1436	1567	1386	4569	4238	5557
Other operating income	35	36	95	108	167	205
Revenue from operations (net)	1471	1603	1481	4677	4405	5762
Other income	62	123	13	216	155	382
Total revenue	1533	1726	1494	4893	4560	6144
Expenses						
Cost of materials consumed	330	331	309	1,027	866	1207
Purchases of stock-in-trade	85	84	95	238	255	343
Changes in inventories of finished goods, work-in-progress and stock-in-trade	2	11	(40)	(3)	18	(5)
Employee benefits expense	262	262	259	804	758	1014
Finance costs	106	111	125	334	362	481
Depreciation and amortisation expense	152	151	147	452	432	579
Other expenses	344	383	407	1,119	1189	1590
Total expenses	1281	1333	1302	3971	3880	5209
Profit before tax	252	393	192	922	680	935
Tax expense						
Current Tax	42	56	39	158	137	194
Deferred Tax	(10)	9	(29)	(7)	(38)	(4)
Total tax expense	32	65	10	151	99	190
Net profit for the period	220	328	182	771	581	745
Other comprehensive income						
Items that will not be reclassified to profit or loss	(5)	(6)	(4)	(14)	(10)	(8)
Income tax relating to items that will not be reclassified to profit or loss	2	2	1	5	3	3
Items that will be reclassified to profit or loss	(44)	(34)	148	(69)	(16)	43
Income tax relating to items that will be reclassified to profit or loss	15	12	(51)	24	6	(15)
Total other comprehensive income	(32)	(26)	94	(54)	(17)	23
Total comprehensive income	188	302	276	717	564	768
Paid-up equity share capital (Face value of Rs. 5 each)	84.62	84.62	84.62	84.62	84.62	84.62
Other Equity excluding Revaluation Reserves						4930
Earnings per share (of Rs. 5/- each) (not annualised for the quarter):						
Basic	12.97	19.40	10.73	45.55	34.32	44.05
Diluted	12.97	19.40	10.73	45.55	34.32	44.05



Notes:

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 27-Jan-2020. The auditor have carried out an audit of the above said results. There is no qualification in the auditor's report on this statement of financial results.
- 2 The Company operates in a single segment i.e Generic Formulation Business.
- 3 The listed non-convertible debentures of the company aggregating Rs. 1764 crores as on 31-Dec-2019 (previous year ended Rs. 1957 crores) are secured by way of first pari passu charge created through mortgage on certain specified immovable & movable assets and hypothecation of identified trademarks of the Company and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
- 4 Effective 01-Apr-2019, the Company has adopted Ind AS 116 Leases using modified retrospective approach. This has resulted in recognizing right of use assets and lease liability as on 01-Apr-2019. The adoption of the standard did not have any material impact to the financial results.
- 5 The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.

For TORRENT PHARMACEUTICALS LIMITED



SAMIR MEHTA
Executive Chairman

Place : Mumbai, Maharashtra

Date : 27-Jan-2020

